We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The novel coronavirus has infected more than 16.65 million across the globe, at the time writing, per worldometers.com. The death toll has surpassed 656,600 worldwide. The United States alone has crossed 4.4 million cases — the highest number globally. This is followed by Brazil with more than 2.45 cases. No wonder, the race for vaccine development has heated up to bring the world back to normal.
Currently, “there are at least a hundred horses in the race, and we've got some leaders up front,” per Marc Poznansky, the director of the Vaccine and Immunotherapy Center at Massachusetts General Hospital, as quoted on Yahoo Finance. The World Health Organization has recognized some 10 prime candidates for vaccines as these have entered clinical trials. Plus, 114 candidate vaccines are in preclinical evaluation stage.
Inside the Prime Candidates
Moderna
U.S. biotech company Moderna (MRNA - Free Report) probably has the most-promising candidate in the field. Moderna’s vaccine for COVID-19 showed it was safe and triggered immune responses in all 45 healthy volunteers in an ongoing early-stage study. Moderna had conducted two tests in May and began phase 3 tests with 30,000 volunteers on Jul 27. Shares jumped 9.2% yesterday.
Moderna shares have gained 308.5% this year. Renaissance IPO ETF (IPO - Free Report) , ETFMG Treatments Testing and Advancements ETF (GERM - Free Report) , Principal Healthcare Innovators Index ETF (BTEC) and VanEck Vectors Biotech ETF (BBH), which are heavy on Moderna, should benefit from the development.
Pfizer
RNA vaccine candidate from the collaboration between U.S.-based Pfizer (PFE - Free Report) and German pharmaceutical company BioNtech is also showing promise. On Jul 27, Pfizer Inc. and BioNTech announced the start of a global (except for China) phase 2/3 safety and efficacy clinical study on 30,000 subjects to evaluate a single nucleoside-modified messenger RNA (modRNA) candidate from their BNT162 mRNA-based vaccine program.
If successful, Pfizer and BioNTech may apply for regulatory review as early as October 2020. The U.S. government already gave an initial order of 100 million doses for $1.95 billion and can procure up to 500 million additional doses. Pfizer has considerable weight in ETFs like First Trust Morningstar Dividend Leaders (FDL) andFirst Trust Nasdaq Pharmaceuticals ETF (FTXH - Free Report) .
AstraZeneca
Then there is a potential vaccine from Oxford University in collaboration with AstraZeneca (AZN - Free Report) and Serum Institute of India. Interim results from the ongoing phase I/II COV001 trial, led by the university, showed AZD1222 was tolerated and generated robust immune responses against the SARS-CoV-2 virus in all evaluated participants.
Late-stage phase II/III trials are currently ongoing in the UK, Brazil and South Africa and are due to start in the United States. Emergent BioSolutions Inc (EBS) said on Jul 27 that it signed a $174 million agreement with AstraZeneca to develop and manufacture the COVID-19 vaccine candidate. Shares of EBS gained 5.5% on Jul 27. In June, AstraZeneca chose Emergent to help produce 300 million doses of its potential COVID-19 vaccine for the United States.
AstraZeneca has exposure in ETFs like IBD Breakout Opportunities ETF (IBD) and VanEck Vectors Pharmaceutical ETF (PPH - Free Report) . Meanwhile, EBS has presence in the likes of ETFMG Treatments Testing and Advancements ETF (GERM - Free Report) and ALPS Medical Breakthroughs ETF (SBIO).
Novavax
Novovax (NVAX - Free Report) is developing its coronavirus vaccine candidate, NVX-CoV2373, in a phase I/II study. The company has also been awarded $1.6 billion by the federal government to support the late-stage development of its vaccine candidate, NVX-CoV2373.
Now, the company is seeking to get its COVID-19 vaccine through clinical trials with help from global contract development and manufacturing organization Fujifilm Diosynth Biotechnologies. Those initial manufactured batches are reserved for the company’s phase 3 study, designed to include 30,000 people in the United States and expected to start this fall. The stock gained a havoc 3,400% this year. Novavax has huge exposure to ETFs Invesco DWA Healthcare Momentum ETF (PTH - Free Report) and GERM.
Vaxart
Vaxart (VXRT - Free Report) is also in the spotlight this year following its efforts to develop an oral tablet vaccine, not injection. In late June, Vaxart’s oral COVID-19 vaccine candidate was selected for investigation in a non-human primate challenge study. The new study will be organized and funded by Operation Warp Speed — a new national program to provide substantial quantities of safe, effective vaccine to Americans by January 2021. Shares of the company have skyrocketed more than 3000% this year.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
COVID-19 Vaccine Push Brings Hope: Stock & ETF Beneficiaries
The novel coronavirus has infected more than 16.65 million across the globe, at the time writing, per worldometers.com. The death toll has surpassed 656,600 worldwide. The United States alone has crossed 4.4 million cases — the highest number globally. This is followed by Brazil with more than 2.45 cases. No wonder, the race for vaccine development has heated up to bring the world back to normal.
Currently, “there are at least a hundred horses in the race, and we've got some leaders up front,” per Marc Poznansky, the director of the Vaccine and Immunotherapy Center at Massachusetts General Hospital, as quoted on Yahoo Finance. The World Health Organization has recognized some 10 prime candidates for vaccines as these have entered clinical trials. Plus, 114 candidate vaccines are in preclinical evaluation stage.
Inside the Prime Candidates
Moderna
U.S. biotech company Moderna (MRNA - Free Report) probably has the most-promising candidate in the field. Moderna’s vaccine for COVID-19 showed it was safe and triggered immune responses in all 45 healthy volunteers in an ongoing early-stage study. Moderna had conducted two tests in May and began phase 3 tests with 30,000 volunteers on Jul 27. Shares jumped 9.2% yesterday.
Moderna shares have gained 308.5% this year. Renaissance IPO ETF (IPO - Free Report) , ETFMG Treatments Testing and Advancements ETF (GERM - Free Report) , Principal Healthcare Innovators Index ETF (BTEC) and VanEck Vectors Biotech ETF (BBH), which are heavy on Moderna, should benefit from the development.
Pfizer
RNA vaccine candidate from the collaboration between U.S.-based Pfizer (PFE - Free Report) and German pharmaceutical company BioNtech is also showing promise. On Jul 27, Pfizer Inc. and BioNTech announced the start of a global (except for China) phase 2/3 safety and efficacy clinical study on 30,000 subjects to evaluate a single nucleoside-modified messenger RNA (modRNA) candidate from their BNT162 mRNA-based vaccine program.
If successful, Pfizer and BioNTech may apply for regulatory review as early as October 2020. The U.S. government already gave an initial order of 100 million doses for $1.95 billion and can procure up to 500 million additional doses. Pfizer has considerable weight in ETFs like First Trust Morningstar Dividend Leaders (FDL) andFirst Trust Nasdaq Pharmaceuticals ETF (FTXH - Free Report) .
AstraZeneca
Then there is a potential vaccine from Oxford University in collaboration with AstraZeneca (AZN - Free Report) and Serum Institute of India. Interim results from the ongoing phase I/II COV001 trial, led by the university, showed AZD1222 was tolerated and generated robust immune responses against the SARS-CoV-2 virus in all evaluated participants.
Late-stage phase II/III trials are currently ongoing in the UK, Brazil and South Africa and are due to start in the United States. Emergent BioSolutions Inc (EBS) said on Jul 27 that it signed a $174 million agreement with AstraZeneca to develop and manufacture the COVID-19 vaccine candidate. Shares of EBS gained 5.5% on Jul 27. In June, AstraZeneca chose Emergent to help produce 300 million doses of its potential COVID-19 vaccine for the United States.
AstraZeneca has exposure in ETFs like IBD Breakout Opportunities ETF (IBD) and VanEck Vectors Pharmaceutical ETF (PPH - Free Report) . Meanwhile, EBS has presence in the likes of ETFMG Treatments Testing and Advancements ETF (GERM - Free Report) and ALPS Medical Breakthroughs ETF (SBIO).
Novavax
Novovax (NVAX - Free Report) is developing its coronavirus vaccine candidate, NVX-CoV2373, in a phase I/II study. The company has also been awarded $1.6 billion by the federal government to support the late-stage development of its vaccine candidate, NVX-CoV2373.
Now, the company is seeking to get its COVID-19 vaccine through clinical trials with help from global contract development and manufacturing organization Fujifilm Diosynth Biotechnologies. Those initial manufactured batches are reserved for the company’s phase 3 study, designed to include 30,000 people in the United States and expected to start this fall. The stock gained a havoc 3,400% this year. Novavax has huge exposure to ETFs Invesco DWA Healthcare Momentum ETF (PTH - Free Report) and GERM.
Vaxart
Vaxart (VXRT - Free Report) is also in the spotlight this year following its efforts to develop an oral tablet vaccine, not injection. In late June, Vaxart’s oral COVID-19 vaccine candidate was selected for investigation in a non-human primate challenge study. The new study will be organized and funded by Operation Warp Speed — a new national program to provide substantial quantities of safe, effective vaccine to Americans by January 2021. Shares of the company have skyrocketed more than 3000% this year.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>